Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms
暂无分享,去创建一个
E. Estey | M. Othus | R. Walter | P. Becker | M. Percival | C. Shaw | A. Halpern | Jacob Appelbaum | Kelda G Schonhoff | L. Shih
[1] B. Ebert,et al. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. , 2022, Blood.
[2] K. Döhner,et al. 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. , 2021, Blood.
[3] E. Estey,et al. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal , 2021, Blood.
[4] E. Estey,et al. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia , 2020, Leukemia & lymphoma.
[5] Markus G. Manz,et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.
[6] Yashma Patel,et al. Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.
[7] E. Estey,et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] B. Wood,et al. Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation , 2013, Leukemia.
[9] E. Estey,et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. , 2013, Blood.
[10] B. Wood,et al. 9-color and 10-color flow cytometry in the clinical laboratory. , 2006, Archives of pathology & laboratory medicine.